Alnylam Pharmaceuticals Inc. continues to make positive strides in the pharmaceutical market, as evidenced by a few notable developments. The company successfully advanced a safety study for Patisiran-LNP in pregnancy and progressed through phase 2 trials for CAA Treatment. Alnylam's Amvuttra has been cleared by the MHRA for treating rare heart disease ATTR-CM. Additionally, the company also reported a 41.67% dip in trading volume to $199 million, making it rank 472nd.
Analysis of Alnylam Pharmaceuticals Inc. stock continues to reflect high-return picks and substantial growth. A significant factor in this development is the FDA approval of their drug Amvuttra for treating progressive heart disease. The company's stock is rising, reflecting the positive market sentiment despite reports of losses. It has also received an outperform rating from BMO Capital and a price target raise to $290 from Cantor Fitzgerald, as well as to $500 by H.C. Wainwright.
The company highlighted progress in its pipeline and platform innovation at a recent R&D day. Alnylam is also advancing in obesity treatment with ALN-4324 and working toward potentially changing the game in liver cancer treatment through a new study on ALN-BCAT.
Alnylam Pharmaceuticals News Analytics from Thu, 31 Oct 2024 07:00:00 GMT to Sat, 19 Jul 2025 23:30:19 GMT - Rating 8 - Innovation 7 - Information 8 - Rumor 1
